Compare Enveric Biosciences Inc (ENVB) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Tapestry, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Tapestry, Inc. trades at $115.82 (market cap $22.62B). The key difference: Tapestry, Inc. is far larger — about 3381.2× Enveric Biosciences Inc's market cap, and Tapestry, Inc. pays a 1.63% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Tapestry, Inc. for 70 Days on average.
| ENVB | TPR | |
|---|---|---|
Market Cap | $6.69M | $22.62B |
Volume | 41,141 | 2,093,865 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $164.78 |
52-Week Low | $1.27 | $98.81 |
Typical Hold Time | 14 Days | 70 Days |
Enterprise Value | -$1.60M | $25.42B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
TPR trades at $115.82, down 0.78% today, with a bearish technical signal but strong analyst support (73% buy ratings). The company shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights international growth in China and Europe, though the stock faces headwinds from tariff risks and Kate Spade execution challenges.
Outlook remains positive with a $174.64 consensus price target suggesting 51% upside, supported by fiscal 2027 margin expansion targets. Key risks include tariff pressures, premium valuation (P/E 15.6), and recent net cash outflows. The stock presents a growth opportunity if international momentum continues and margin targets are achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
